Targeting MEK-RAF Complex to Overcome CRAF Mediated Resistance & Drive Superior Anti-Tumor Activity in RAS/RAF Altered Cancers

Time: 2:15 pm
day: Day 2 Track A PM


  • Showcasing how trapping MEK-RAF in an inactive complex blocks CRAF mediated MEK reactivation that limits the efficacy of approved MEK inhibitors in RAS mutant tumors
  • Examining how more complete MAPK pathway inhibition results in potent anti-tumor activity across a broad range of RAS/RAF altered cancer cell lines/models
  • Understanding how intermittent dosing schedules that enable transient drug exposure above IC90 followed by low exposure recovery improve therapeutic window